Immunotherapy in Oncology Drug Pipeline Update
|出版商||BioSeeker Group AB||商品編碼||171759|
Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators in oncology drug development into one source.
There are today 830 companies plus partners developing 1578 cancer immunotherapy drugs in 4062 developmental projects in cancer. In addition, there are 19 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 624 drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 535 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 485 out of the 491 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 77 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug name & Synonyms
Target Expression Profile
Principal Company & Partners
Target and Molecular Function of Target
Fillings and Approvals
Phase IV Data
Phase III Data
Phase II Data
Phase I Data
Phase 0 Data
Dynamic Report Generator